ArticleJournal of translational medicine2025
Proteomic and metabolomic analysis of platelet related samples reveals energy metabolism disorders in hepatocellular carcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-omics integration model of exosome metabolomics and PD-1/PD-L1 expression for early prediction of immunotherapy efficacy in advanced liver cancer.Scientific reports · 2026Article
- Glutamine Starvation Induces Ferroptosis in NSCLC via AMPK/PDZD8-Mediated Ferritinophagy.Nutrients · 2026Article
- The impact of metabolic reprogramming in hepatocellular carcinoma on T cell.Frontiers in immunology · 2025Review
- Multi-Omics Biomarker Signatures for Precision Diagnosis and Prognosis in Primary Liver Cancer: A Literature Review.BioFactors (Oxford, England)Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most prevalent cancers in the world. Platelets play an important role in thrombosis, inflammation, and tumors. This study tries to gain a pathway-based view of platelets-related samples for understanding metabolic disorders and identifying novel biomarkers in HCC by combining proteomics and metabolomics.
methodsForty-five HCC patients and thirty-four healthy controls were included in the study. We performed label-free proteomic analysis of platelets from 14 HCC patients and 14 healthy controls. Target metabolomics analysis was performed on platelet-rich plasma (PRP) from 31 HCC patients and 20 healthy controls. Western blotting was performed to validate the results of proteomics. Glutamine (Gln) deprivation assay was conducted to evaluate the effect of Gln metabolism on the platelet-induced proliferation, migration, and invasion of HCC cells.
resultsProteomics analysis revealed dysregulation of platelets function and energy metabolism in HCC patients compared with healthy controls. Target metabolomics analysis showed widespread dysregulation of amino acids in HCC patients. Integrating analysis of differential proteins and metabolites revealed five significant dysregulated pathways in HCC patients. Western blotting validation results showed that the expression levels of SDHB, CISY, and FUMH were significantly up-regulated in HCC patients compared to healthy controls, which was consistent with the proteomics findings. Biological function revealed that Gln-free weakens the ability of platelet-induced proliferation, migration, and invasion of HCC cells. Diagnostic evaluation demonstrated superior discriminatory power for SDHB (AUC = 0.929) compared to alpha-fetoprotein (AFP) in platelet proteomics. Furthermore, a triad of tricarboxylic acid cycle intermediates (succinic acid, fumaric acid, and malic acid) significantly enhanced the AUC, specificity, and sensitivity of distinguishing HCC patients from healthy controls compared to AFP.
conclusionsThrough multi-omics characterization of platelets-related samples, the network of altered proteins and metabolites provides a comprehensive view of altered metabolism in the peripheral circulation of HCC patients. Gln deprivation inhibited the ability of platelet-induced malignant biology function in HCC cells. Collectively, proteomics and metabolomics provide evidence for possible future non-invasive or minimally invasive biopsies for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.